Valeant Pharmaceuticals Intl
13F holders, Q4 2025 (December 31)1holders
0new positions
0sold out
$6.95avg. 13F price*
At the end of Q4 2025, 1 institutions reported holding Valeant Pharmaceuticals Intl in their 13F filings, unchanged from Q3 2025. 0 opened new positions and 0 sold out. The largest holder was Bruce & Co., Inc. ($862K).
- Company
- Valeant Pharmaceuticals Intl
- Filed as
- Bausch Health (Q4 2025)
- CUSIP
- 91911K102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 47,000 shares sold, net −47,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Bruce & Co., Inc. | 0.27% | Reduce -27.5% | 124,000 | $862K |
"% of holder's portfolio" is VALEANT PHARMACEUTICALS INTL's weight in each manager's 13F, not the share of Valeant Pharmaceuticals Intl the manager owns.